Viridian Therapeutics Inc Aktie News

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Kommerzialisierung potenziell erstklassiger Arzneimittel für Autoimmun- und seltene Erkrankungen konzentriert, gab heute bekannt, dass das Senior Management an einem Fireside-Chat auf der 21. jährlichen Healthcare-Konferenz von Wells Fargo am D...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Kommerzialisierung potenziell erstklassiger Medikamente für Autoimmun- und seltene Krankheiten konzentriert, berichtete heute über jüngste geschäftliche Höhepunkte und Finanzergebnisse für das zum 30. Juni 2026 beendete zweite Quartal. „Wir sin...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, deb...

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to sys...

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken magmatic sulphide system in Labrador, where drilling in 2024 intersected copper grades up to 4.15% Cu (see news release dated November 26, 2024). The Company's recently announced 50-hole drill pro...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat...

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at rou...

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announce that it has entered into a binding subscription agreement with Pavilion Flow- Through L.P. (2026) 1 (the “Investor”) in respect of a non-brokered private placement (the “Private Placement”) of flow-through units of the Company (the “Units”) at a price of $0.52 per Unit ...